Future Directions in Bronchiectasis Research

Rosanel Amaro; Lídia Perea; Oriol Sibila

doi:10.1016/j.ccm.2021.12.005

Future Directions in Bronchiectasis Research

Clin Chest Med. 2022 Mar;43(1):179-187. doi: 10.1016/j.ccm.2021.12.005.

Authors

Rosanel Amaro¹, Lídia Perea², Oriol Sibila³

Affiliations

¹ Department of Pneumology, Respiratory Institute, Hospital Clínic, Barcelona, Spain. Electronic address: ramaro@clinic.cat.
² Department of Inflammation and Reparation in Respiratory Diseases, IDIBAPS, CIBER, Barcelona, Spain.
³ Department of Pneumology, Respiratory Institute, Hospital Clínic, Barcelona, Spain. Electronic address: osibila@clinic.cat.

PMID: 35236557
DOI: 10.1016/j.ccm.2021.12.005

Abstract

Bronchiectasis treatment is challenging, and many recent randomized controlled trials have failed to prove any clinical improvement. The most reasonable explanation for that problem is the high heterogeneity of patients' groups. For that reason, there is an urgent need to find new biomarkers to better stratify patients. The present chapter addresses the future directions in biomarkers, omics technologies, endotypes, and new treatments toward a personalized medicine in the field of bronchiectasis.

Keywords: Biomarkers; Endotypes; Omics; Personalized medicine.

Publication types

Review

MeSH terms

Bronchiectasis* / therapy
Humans
Precision Medicine